Abstract
In recent decades our understanding of immune cell activation and homeostasis has significantly expanded. Such progress helped to better define the cellular, molecular, and epigenetic networks involved in the immune response in the tumor microenvironment and renewed the enthusiasm towards the potential power of cancer immunotherapy. However, successful translation of novel mechanistic discoveries into effective immunotherapy was hindered by a number of obstacles, among them the ability of tumors to tolerize host lymphocytes rendering them functionally incompetent and the tumors ability to evade antigen-specific immune recognition through a variety of genetic, epigenetic, and stromal factors. These immunosuppressive strategies have, thus far, blunted our efforts to effectively unleash anti-cancer immunity. Fortunately, the wealth of new information regarding the interactions between tumors and the immune system and the regulation of certain highly antigenic tumor proteins has led to novel approaches with the potential to render cancer cells helpless towards immune attack. Here we summarize recent findings on cancer-induced T-lymphocyte tolerance and discuss a novel “vaccinate-induce” strategy conceived to counteract these effects at an epigenetic level.
Keywords: Histone deacetylase, tolerance, cancer testis antigen, cancer vaccine, DNA methylation, chromatin, immunotherapy
Current Pharmaceutical Design
Title: Circumventing Immune Tolerance Through Epigenetic Modification
Volume: 16 Issue: 3
Author(s): Jason A. Dubovsky, Alejandro Villagra, John J. Powers, Hong-Wei Wang, Javier Pinilla-Ibarz and Eduardo M. Sotomayor
Affiliation:
Keywords: Histone deacetylase, tolerance, cancer testis antigen, cancer vaccine, DNA methylation, chromatin, immunotherapy
Abstract: In recent decades our understanding of immune cell activation and homeostasis has significantly expanded. Such progress helped to better define the cellular, molecular, and epigenetic networks involved in the immune response in the tumor microenvironment and renewed the enthusiasm towards the potential power of cancer immunotherapy. However, successful translation of novel mechanistic discoveries into effective immunotherapy was hindered by a number of obstacles, among them the ability of tumors to tolerize host lymphocytes rendering them functionally incompetent and the tumors ability to evade antigen-specific immune recognition through a variety of genetic, epigenetic, and stromal factors. These immunosuppressive strategies have, thus far, blunted our efforts to effectively unleash anti-cancer immunity. Fortunately, the wealth of new information regarding the interactions between tumors and the immune system and the regulation of certain highly antigenic tumor proteins has led to novel approaches with the potential to render cancer cells helpless towards immune attack. Here we summarize recent findings on cancer-induced T-lymphocyte tolerance and discuss a novel “vaccinate-induce” strategy conceived to counteract these effects at an epigenetic level.
Export Options
About this article
Cite this article as:
Dubovsky A. Jason, Villagra Alejandro, Powers J. John, Wang Hong-Wei, Pinilla-Ibarz Javier and Sotomayor M. Eduardo, Circumventing Immune Tolerance Through Epigenetic Modification, Current Pharmaceutical Design 2010; 16 (3) . https://dx.doi.org/10.2174/138161210790170120
DOI https://dx.doi.org/10.2174/138161210790170120 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Inflammation and Cancer: In Medio Stat Nano
Current Medicinal Chemistry Radiolabeling Methods and Nuclear Imaging Techniques in the Design of New Polymeric Carriers for Cancer Therapy
Current Applied Polymer Science The Relationship Between Oncogene Expression and Clinical Outcome in Endometrial Carcinoma
Current Cancer Drug Targets Role of microRNAs in Gynecological Pathology
Current Medicinal Chemistry TRP Channels and Cancer: New Targets for Diagnosis and Chemotherapy
Endocrine, Metabolic & Immune Disorders - Drug Targets Anti-Angiogenic Therapy: Strategies to Develop Potent VEGFR-2 Tyrosine Kinase Inhibitors and Future Prospect
Current Medicinal Chemistry Immunotherapy in Breast Cancer- Paving New Roads?
Current Molecular Pharmacology Technetium-99m – New Production and Processing Strategies to Provide Adequate Levels for SPECT Imaging
Current Radiopharmaceuticals Specialisation of the Tropomyosin Composition of Actin Filaments Provides New Potential Targets for Chemotherapy
Current Cancer Drug Targets The Human L1 Element: A Potential Biomarker in Cancer Prognosis, Current Status and Future Directions
Current Molecular Medicine Recent Advances in the Characterization of Genetic Factors Involved in Human Susceptibility to Infection by Schistosomiasis
Current Genomics Surface Markers of Cancer Stem Cells in Solid Tumors
Current Stem Cell Research & Therapy Pharmacogenomics of Xenobiotic Metabolizing Enzymes in South American Populations
Current Pharmacogenomics Advances in Nanomedicine Towards Clinical Application in Oncology and Immunology
Current Pharmaceutical Biotechnology Near-infrared Light Activatable Multimodal Gold Nanostructures Platform: An Emerging Paradigm for Cancer Therapy
Current Cancer Drug Targets A Quantitative Proteomics Approach in the Study of MicroRNA 181a in HepG2 Cells
Current Proteomics Furan-induced Oxidative Stress and DNA Damage in Diabetic and Nondiabetic Rats’ Blood and Protective Effect of Lycopene
Current Nutrition & Food Science Decreased lncRNA SNHG16 Accelerates Oxidative Stress Induced Pathological Angiogenesis in Human Retinal Microvascular Endothelial Cells by Regulating miR-195/mfn2 Axis
Current Pharmaceutical Design Molecular Mechanism of Anti-tumor Effect by Triptolide in Hematological Malignancies
Current Signal Transduction Therapy Targeting Synthetic Lethality in DNA Damage Repair Pathways as an Anti-Cancer Strategy
Current Drug Targets